Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® - Contacts and Locations

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

This study is not yet open for participant recruitment.

Study NCT00668200. Last updated on April 25, 2008. Information provided by Novartis

Please refer to this study by its ClinicalTrials.gov identifier: NCT00668200

Contacts


Contact: Novartis Pharmaceuticals, New Jersey	862-778-8300

Locations


United States, Arizona

	Tucson, Arizona, United States, 85723

United States, Colorado

	Aurora, Colorado, United States, 80010

United States, Florida

	Jacksonville, Florida, United States, 32209

United States, Illinois

	Maywood, Illinois, United States, 60153

United States, Rhode Island

	Providence, Rhode Island, United States, 02908

United States, Texas

	Fort Worth, Texas, United States, 76107

	Houston, Texas, United States, 77004

	Dallas, Texas, United States, 75216

	Waco, Texas, United States, 76708

Sponsors and Collaborators

Novartis